Horse | Dose (mg) | IC50 (ng/mL) |
I
max
| kout (1/h) | ALPS1 (R/h) | ALPS2 (R/h) | kLPS1 (1/h) | kLPS2 (1/h) |
γ
1
|
γ
2
|
---|
tv
| na | 4.0 | 0.84 | 0.44 | 3.5 | 48.4 | 0.04 | 0.65 | 3.9 | 0.8 |
F | 0.01 | 3.4 | 0.85 | 0.39 | 3.4 | 41.2 | 0.07 | 0.68 | 2.2 | 0.6 |
C | 0.03 | 2.9 | 0.85 | 0.59 | 3.4 | 43.3 | 0.06 | 0.68 | 1.6 | 0.6 |
B | 0.1 | 3.4 | 0.86 | 0.35 | 3.4 | 40.9 | 0.05 | 0.68 | 4.9 | 0.5 |
A | 0.3 | 3.1 | 0.85 | 0.39 | 3.4 | 47.5 | 0.007 | 0.69 | 12.8 | 1.5 |
D | 1 | 3.4 | 0.84 | 0.33 | 3.4 | 41.7 | 0.08 | 0.67 | 4.0 | 0.6 |
E | 3 | 3.9 | 0.85 | 0.39 | 3.4 | 41.2 | 0.07 | 0.68 | 2.1 | 0.6 |
- Where tv is the typical value for the population, dose is the amount dexamethasone administered into the joint, IC50, Imax and kout are the potency value, the efficacy value (with a maximal possible value of 1) and fractional elimination rate of the response, respectively. ALPS1, ALPS2, kLPS1, kLPS2, γ1 and γ2 are maximal input rates, the rate constant controlling the time development of the challenge function and exponents shaping (amplifying) the response to the LPS-challenge, respectively. Note that shrinkage was high (> 0.3) for IC50, Imax, ALPS1, ALPS2 and kLPS2 due to a poor estimate of the random component of the model for these parameters and corresponding post hoc values were shrinked toward their population values